Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (15095)	2/14/1998 6:49:00 PM
From: tonyt	Respond to of 32384

Thanks for the link. I appreciate the fact that some on this board will do a little research instead of just trashing an analyst (i.e. ref to "Crazy"). Next thing, they'll be accusing this analyst of having a grudge against Ligand :-) I hope Ligand is successful, however, they are a looong way from market with this drug.

To: squetch who wrote (15095)	2/14/1998 6:53:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Stan, I did a little more research and found Americal's website: americalsec.com Of course they don't list Ligand (maker of Targretin), but do list Zeneca (ZEN), makers of Tamoxifen. What a coincidence. (They also list AMLN, AGPH, and ERGO)

To: squetch who wrote (15095)	2/14/1998 7:02:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Stan, Speaking of LGND's drug, Targretin, the four analysts that cover LGND (Bear Stearns, Robertson Stephens, Lehman Brothers, and Hambrecht & Quist) all expect an NDA filing on oral Targretin this year (or early next year at the latest). Most investors would consider such a time frame as "soon". I guess day traders measure time in seconds, so the end of this year seems to them to be a looong way to market.

To: squetch who wrote (15095)	2/14/1998 7:20:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Speaking of markets, the "Beyond Tamoxifen" paper suggests 3 major breast cancer markets for Targretin. Since Targretin works better than Tamoxifen in the breast cancer model and produces fewer side effects (it actually inhibits the uterine growth stimulating properties of Tamoxifen), one application would be as monotherapy. Since Targretin also synergizes with Tamoxifen, and second approach would be combination therapy. Tumors frequently become resistant to Tamoxifen and a study of patients who had been on Tamoxifen for more than 5 years found that there was no benefit beyond the five years. Combination treatment with Tamoxifen, or other SERMs such as Evista (Raloxifene), Droloxifene, CP-366,156, or TSE424 would allow the drugs to be used at lower concentrations to minimize side effects and further resistance. A third application would be to treat patients who did become resistant to Tamoxifen. Of course all of these trials would take considerable time and money. However, since oral Targretin will likely win approval for CTCL next year (NDA is slated for this year), off label use could be very significant. As shown by LGND's record volume of almost 2 million shares on Thursday, as well as new posters to this site, there is considerable interest in breast cancer treatment (and prevention). MD's frequently prescribe off-label use for treatment of life threatening conditions, especially if some efficacy has already been demonstrated in Phase II trials. It sounds like LGND is considering Phase II trials for all of the above. CEO Robinson has recently said that the breast cancer data keeps getting better and better and LGND will aggressively pursue clinical trials targeting advanced breast cancer. Looks like it's going to be a very good year.